Sepantronium bromide

Drug Profile

Sepantronium bromide

Alternative Names: YM-155; YM155 monobromide

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Antineoplastics; Naphthoquinones; Small molecules
  • Mechanism of Action BIRC5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Diffuse large B cell lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a preclinical studies in Non-Hodgkin's lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 01 Aug 2013 Discontinued - Phase-I for Non-Hodgkin's lymphoma in Japan (IV)
  • 01 Aug 2013 Discontinued - Phase-II for Non-Hodgkin's lymphoma in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top